19 results about "Adalimumab" patented technology

The invention provides application of an Aars1 gene in regulation and control of expression of an exogenous recombinant protein, and belongs to the technical fields of recombinant protein expression, gene engineering and cell culture. According to the CHO cell line, shRNA fragments of targeted Aars1 genes are inserted and integrated into piggyBac transposon vectors, a recombinant vector for inhibiting / silencing the Aars1 genes and an Aars1 low-expression CHO cell line are constructed, the CHO cell line can remarkably reduce the mRNA expression level of the Aars1, meanwhile, the CHO cell line serves as a host cell for recombinant protein expression, and compared with a wild type CHO cell line, the CHO cell line has the advantages that the expression level of the CHO cell line is greatly improved; the recombinant adalimumab can improve the expression quantity of recombinant protein (the expression quantity of the recombinant adalimumab is increased by 3.1 + / -0.18 times), effectively overcomes the problem of low expression level of the existing CHO cell expression system, and can be used for further constructing a recombinant protein expression system or kit.

The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-α4β7 antibody, a TNFα antagonist, and an immunomodulator.

Stable adalimumab formulations are disclosed.

A pharmaceutical composition comprises a buffer-less aqueous formulation of adalimumab, a salt, a polyol, and a polysorbate. The formulation is suitable for injection.

The present invention relates to the technical field of genetic engineering, and in particular to a use of let-7a in CHO cell recombinant protein expression and an expression system. According to the present invention, the amount of miRNA let-7a in a CHO cell recombinant protein expression system is increased to increase the expression level of a recombinant protein; and an experiment is designed to verify that the direct transfection of let-7a mimics into the CHO cell recombinant protein expression system can increase the expression level of a target protein, for example, adalimumab. In addition, experiments verify that the insertion of a let-7a mimics encoding nucleic acid sequence into a starting vector to construct a let-7a overexpression vector, the transfection of the let-7a overexpression vector into the CHO cell recombinant protein expression system, and the increase of the amount of miRNA let-7a more efficiently increase the expression level of the target protein.

The invention relates to the technical field of recombinant protein expression and cell culture, in particular to a serum-free culture medium additive, a serum-free cell culture medium and application. The myricetin provided by the invention is used as a serum-free culture medium additive, is particularly used for CHO cell recombinant antibody expression, and is particularly used for suspension culture, the final concentration in the CHO serum-free culture medium is 3-6 [mu] M, normal growth and metabolism of cells are not influenced, the myricetin acts on the CHO cells by controlling oxidative stress, and the growth of the CHO cells is inhibited. And the myricetin can change the quality attribute of the adalimumab, so that the production cost of biological products is reduced.

Stable adalimumab formulations are disclosed.

The invention discloses an RNA (Ribonucleic Acid) composition for coding adalimumab and application of the RNA composition. The RNA composition comprises an mRNA (messenger ribonucleic acid) composition and / or a circRNA composition. The invention provides a light-chain RNA construct and a heavy-chain RNA construct for coding adalimumab, and a composition comprising the light-chain RNA construct and the heavy-chain RNA construct for coding adalimumab and carrier particles, which can be used for effectively treating TNF-alpha related diseases or symptoms such as rheumatoid arthritis and inflammatory bowel diseases.

The present application relates to a method for preparing an antibody group and an antibody group prepared by the method, which can prepare a high-purity and high-quality desired antibody group by removing impurities without using an expensive protein A column, and in particular, can achieve process automation and greatly reduce production costs.

The invention relates to a retina-infected AAV vector, an adalimumab and application thereof. Specifically, the invention provides an easily available AAV vector capable of efficiently infecting the retina and application thereof, and also provides a high-expression adalimumab coding sequence and application thereof. According to the AAV vector and the adalimumab coding sequence, on one hand, the side effect can be reduced through local administration and relatively low dosage, and on the other hand, the lifelong benefit effect of one-time administration can be realized by utilizing the long-term expression ability.

The invention relates to an anti-adalimumab nano antibody and application thereof, an Adalimumab F (ab ') fragment is used as an antigen to immunize alpaca, and the nano antibody is obtained by screening in a memory B cell culture mode; the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the nano antibody are respectively as shown in SEQ ID No. 1 to SEQ ID No. 3, or the amino acid sequences of the complementary determining regions CDR1, CDR2 and CDR3 of the nano antibody are respectively as shown in SEQ ID No. 4 to SEQ ID No. 6. The nano antibody has strong adalimumab binding capacity and high specificity, greatly improves the detection sensitivity and accuracy, can be used for drug monitoring, drug resistance research and drug interaction analysis, can be expanded to biological preparation quality control, clinical diagnosis and scientific research tools, and has wide application prospects.

The invention provides targeted precise immunotherapy by applying a biological protein nano-robot to carry a biological agent and a preparation method of the biological protein nano-robot, and relates to the field of immunotherapy, the preparation method comprises the following steps: S100, preparing a serum albumin aqueous solution with the serum albumin concentration of 5-10% w / v, and a phosphate buffer solution with the pH value of 7.4 as a solvent; and S200, preparing an organic solution of a hydrophobic anti-rheumatism drug, wherein the drug is one or more of adalimumab, jucuiliumab, ezetizumab, tetronigerb, tolzumab and rituximab. When the albumin nano-robot targeting drug is used for treating rheumatism, effective targeting can be realized by utilizing the chemotactic effect of the albumin nano-robot targeting drug for immunotherapy on high-expression iNOS and ROS in an immune microenvironment, and the released anti-rheumatism drug and nitric oxide play a synergistic effect for combined treatment; wherein the anti-rheumatism medicine and nitric oxide (NO) generated in the targeting process of the nano-robot can jointly start immune circulation in vivo, and the anti-rheumatism medicine and the nitric oxide (NO) cooperate with the chemotherapy medicine to achieve the killing effect, so that the combined treatment effect is achieved.

The invention provides a monoclonal antibody for recognizing a TNF (Tumor Necrosis Factor) alpha-CRM197 vaccine and a preparation method of the monoclonal antibody. The affinity of the monoclonal antibody prepared by screening to a TNF alpha-CRM197 vaccine is higher than that of TNF alpha, the monoclonal antibody can be used for specifically detecting the relative antigen amount (in vitro relative titer) in the TNF alpha-CRM197 vaccine after being combined with adalimumab, and the monoclonal antibody hardly responds to free TNF alpha.

The invention belongs to the technical field of biological medicine, and discloses an adeno-associated virus mutant and application thereof. The adeno-associated virus mutant capable of delivering the adalimumab or the Ozorezumab nano-antibody is produced by co-transfecting a recombinant plasmid of a sequence for coding the adalimumab or the Ozorezumab nano-antibody, an auxiliary plasmid and a packaging plasmid into a cell, and the disease progress of an arthritis mouse model can be safely and effectively relieved. According to the invention, an optimal administration scheme selection is provided for research on joint specific gene therapy, and a new way is provided for clinical treatment of arthritis.

The present application belongs to the field of pharmacy, and provides an adalimumab composition, wherein aspartic acid is used as a buffer system. The adalimumab pharmaceutical composition has high physical and chemical stability, and can be stored for a long time.

This invention provides an antibody-glucocorticoid conjugate (ADC) or a pharmaceutically acceptable salt or solvate thereof, and its uses. The structural formula of the ADC or its pharmaceutically acceptable salt or solvate is shown in the text. The ADC provided by this invention can significantly affect the activation level of glucocorticoid-mediated signaling pathways, thereby producing significant anti-inflammatory activity; it has good plasma stability, which can avoid premature release of glucocorticoid molecules in systemic circulation; it has good endocytic capacity and human lysosomal cleavage capacity, which can achieve targeted absorption of the ADC and rapid release of small glucocorticoid molecules, thereby improving efficacy. In mouse contact hypersensitivity models and rat rheumatoid arthritis models, it showed excellent anti-inflammatory activity, significantly superior to adalimumab and the control group.

The application provides a monoclonal antibody for identifying a TNF alpha-CRM197 vaccine and a preparation method thereof. The monoclonal antibody prepared through screening has higher affinity to the TNF alpha-CRM197 vaccine than to TNF alpha, and after being combined with adalimumab, can be used for specifically detecting the relative antigen amount (in vitro relative titer) in the TNF alpha-CRM197 vaccine, and hardly responds to free TNF alpha.

The application provides a kind of CHO cell-derived exosome miRNA in the application of regulating recombinant protein expression, and belongs to the technical field of biological medicine.The application provides a kind of CHO cell-derived exosome miRNA in the application of regulating recombinant protein expression, and the miRNA is cgr-miR-92a-3p, nucleotide sequence is shown as SEQ ID NO:1.The application finds that the level of exosome miR-92a-3p of CHO cell is down-regulated by transfecting miRNA inhibitor, and the expression level of adalimumab (recombinant protein) is significantly increased, which is expected to provide a new method for improving the expression of CHO cell recombinant protein.

The invention relates to the technical field of recombinant protein expression and cell culture, in particular to application of safflower leaf exosome-like nano-vesicles to improvement of CHO cell line recombinant protein expression quantity. Specifically, safflower leaf exosome-like nano-vesicles with a specific concentration are added into a CHO cell serum-free culture medium. Compared with a traditional safflower leaf water extract, the additive can remarkably improve the living cell density in the culture process, prolong the culture period, inhibit cell apoptosis and enhance the cell oxidation resistance. Experiments prove that the cell specificity productivity can be effectively improved, and the expression quantity of adalimumab, motuzumab and other target antibodies is remarkably increased. On the premise that the scale of the bioreactor is not enlarged, the yield of the culture medium in unit volume is increased, the consumption and production cost of the culture medium are reduced, and an innovative culture strategy is provided for efficient and economical production of the monoclonal antibody.